Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
West German Cancer Center, Heidelberg, Germany.
Oncol Res Treat. 2022;45(1-2):18-25. doi: 10.1159/000521079. Epub 2021 Nov 24.
A variety of therapeutic approaches are employed to treat patients suffering from breast cancer. Likewise, a broad spectrum of imaging ligands has been introduced for noninvasive positron emission tomography/computed tomography (PET/CT) imaging to enable comprehensive tumor characterization and more accurate response evaluation.
In recent years, novel radioactively labeled ligands have been developed for PET/CT imaging in metastatic breast cancer. One promising tracer is [18F]fluoroestradiol, which was recently approved by the Food and Drug Administration. It can be used for a whole-body assessment of estrogen receptor status. Another radionuclide currently under development is [68Ga]Ga-fibroblast-activation-protein inhibitor. In addition to new radionuclides, the field of application for existing tracers like [18F]fluorodeoxyglucose (FDG) was broadened. It has been shown that an early therapeutic response to various therapies can be detected by [18F]FDG PET/CT, which leads to early treatment optimization. Key Message: In this review, we highlighted new tracers and applications of PET/CT imaging as well as therapeutic approaches in patients with advanced breast cancer. Furthermore, we give an outlook on the application of artificial intelligence, immunoPET, and liquid biopsy.
目前有多种治疗方法可用于治疗乳腺癌患者。同样，也引入了广泛的成像配体，用于非侵入性正电子发射断层扫描/计算机断层扫描（PET/CT）成像，以实现全面的肿瘤特征描述和更准确的反应评估。
近年来，新型放射性标记配体已被开发用于转移性乳腺癌的 PET/CT 成像。一种很有前途的示踪剂是[18F]氟雌二醇，它最近获得了美国食品和药物管理局的批准。它可用于全身评估雌激素受体状态。另一种正在开发中的放射性核素是[68Ga]Ga-成纤维细胞激活蛋白抑制剂。除了新的放射性核素外，[18F]氟脱氧葡萄糖（FDG）等现有示踪剂的应用范围也有所扩大。研究表明，[18F]FDG PET/CT 可检测到各种治疗方法的早期治疗反应，从而实现早期治疗优化。
在这篇综述中，我们强调了新型示踪剂以及 PET/CT 成像在晚期乳腺癌患者中的治疗方法的应用，并展望了人工智能、免疫 PET 和液体活检的应用。
